Search the Newsreel

Myers Industries Inc (MYE) Institutional Confidence

The article analyzes the institutional confidence in Myers Industries Inc (MYE), noting its high score of 10.00, which ranks it first in the Containers & Packaging industry. Institutional shareholding has increased to 104.26%, with Richard Pzena being the largest individual institutional shareholder. The report …

Bristol-Myers Squibb Company Revenue Breakdown – HAM:BRM

Bristol-Myers Squibb Company (HAM:BRM) generated €41.03 billion in revenue last year, primarily from its Innovative Medicines segment. This marks a decrease from the previous year's €46.66 billion. The United States was the largest contributor to revenue, accounting for €28.33 billion.

Myers Industries Inc (MYE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Myers Industries Inc (MYE) by business segment and by region, using data updated on April 6. The largest proportion of revenue comes from the Industrial segment, followed by Auto Aftermarket, with the United States accounting for …

Bristol-Myers Squibb Company Celegne Contingent Value Revenue Breakdown – BOATS:CELG/R

This article provides a brief overview of Bristol-Myers Squibb Company's Celgene Contingent Value financials, specifically focusing on its revenue breakdown for the Innovative Medicines segment and geographical contributions. Last year, the company generated $48.19 billion USD from Innovative Medicines, with the largest portion, $33.28 …

Myers Industries Inc (MYE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a detailed historical overview of dividend payouts for Myers Industries Inc (MYE), including specific dates for ex-dividend, record, and payment. It highlights that the company has distributed a total of $80.06 million in dividends over the past five years, with recurring …

Bristol-Myers Squibb Expands Pipeline With New First-in-Human Trial for BMS-986533

Bristol-Myers Squibb (BMY) has initiated a first-in-human Phase 1 trial for BMS-986533, an oral drug, to evaluate its safety, pharmacokinetics, and dosing in healthy volunteers. This randomized, double-blind, placebo-controlled study includes multiple dosing schemes and assesses interactions with common medications. The trial, which began …

MYE|Myers Industries Inc|Price:31.030|Chg%:+0.070

Myers Industries Inc (MYE) closed at $31.420, up 1.49%, with a market cap of $1.18 billion. The company manufactures sustainable plastic and metal products and distributes tools and supplies for the automotive industry. Its top executives include CEO Aaron M. Schapper, and as of …

Oak Associates Ltd. OH Acquires New Position in Bristol Myers Squibb Company $BMY

Oak Associates Ltd. OH has acquired a new position in Bristol Myers Squibb Company, purchasing 131,790 shares valued at approximately $8.0 million during the first quarter. Bristol Myers Squibb reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, and announced a …

Bristol Myers Squibb Company $BMY Stake Raised by Sei Investments Co.

Sei Investments Co. increased its stake in Bristol Myers Squibb (NYSE:BMY) by 8.2% in the first quarter, bringing its total holdings to over 2.19 million shares valued at $133 million. Several other institutional investors also adjusted their positions in BMY. Analysts have a mixed …

BMY|Bristol-Myers Squibb Co|Price:63.745|Chg%:-1.095

Bristol Myers Squibb Takes Drugmaker Week Rank at 92.6% of Its Yearly Range

BMY added 5.5% in the latest week and led its US Drug Manufacturers - General group, but Sharemaestro Market Dynamics have not fully confirmed the move.

Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts

Bristol Myers Squibb (BMY) saw a 1.05% gain, closing at $61.40, while the broader market declined. The stock has increased by 10.47% over the past month, outperforming both the Medical sector and the S&P 500. Analysts anticipate an 8.9% year-over-year earnings growth for its …

SC man burned while using a gas can and later died. Estate now suing the company

A federal wrongful-death lawsuit has been filed against Myers Industries and several Scepter-related companies by the estate of Jack Dale Still. The lawsuit alleges that a plastic gasoline container without a flame-mitigation device exploded, causing fatal burns to Still while he was trying to …

DOL Brief Sides With Bristol-Myers in PRT Appeal

The U.S. Department of Labor filed an amicus brief supporting Bristol-Myers Squibb in an appeal, arguing that retirees lack Article III standing to sue over pension risk transfers if they continue to receive full benefits. This action, along with a similar brief for Lockheed …

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains

Bristol Myers Squibb Co. (BMY) shares rose by 1.23% on Thursday, closing at $61.51, despite a general market downturn where the S&P 500 and Dow Jones Industrial Average both fell. The stock, however, still underperformed compared to some competitors and ended 2.19% below its …

Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth

Bristol Myers Squibb (BMY) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2026, with Wall Street anticipating $1.59 EPS on $11.67 billion in revenue. The company has a Zacks Earnings ESP of +0.51% and a …

Myers Industries (MYE) Expected to Announce Earnings on Thursday

Myers Industries (MYE) is anticipated to release its Q2 2026 earnings before the market opens on Thursday, July 30th. Analysts are forecasting earnings of $0.36 per share on revenues of $166.0 million. The company previously exceeded profit estimates in its last quarterly report but …

DOL Anchors Wave of Briefs Backing Bristol-Myers in PRT Appeal

The U.S. Department of Labor has filed an amicus brief supporting Bristol-Myers Squibb in a pension risk transfer (PRT) appeal, joining business groups, insurers, and states. They argue that retirees lack Article III standing as they still receive full benefits and that allowing such …

Bristol Myers Squibb (BMY) Wins FDA Filing And Nvidia Tie Up, Is It Still Undervalued?

Bristol-Myers Squibb (BMY) has gained momentum following FDA acceptance of its New Drug Application for mezigdomide and an AI collaboration with Nvidia for drug discovery. The company is currently considered 3.2% undervalued with a fair value of $62.96, despite existing risks related to patent …

Mastermyne Exceeds FY26 Guidance with $237.7M Revenue and $20.3M EBITDA

Mastermyne (ASX:MYE) Shares Surge as FY26 Results Beat Guidance and Order Book Expands

Bristol Myers Squibb (BMY) Opens 427,000 Square Foot San Diego Hub For AI Drug Discovery

Bristol Myers Squibb (BMY) has opened a significant 427,000 square foot R&D hub in San Diego, integrating NVIDIA-powered AI infrastructure to accelerate drug discovery. This initiative aims to enhance the speed and efficiency of its oncology, cardiovascular, and immunology programs, potentially offsetting patent expiries …

WashU announces new academic-industry collaboration with Bristol Myers Squibb

Washington University in St. Louis and Bristol Myers Squibb have initiated a multiyear collaboration to foster scientific exchange and advance drug development in neuroscience. This partnership will provide WashU medical and research trainees with opportunities to work alongside Bristol Myers Squibb scientists and will …

Lobbying Update: $3,160,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed

A recent lobbying disclosure reveals that Bristol-Myers Squibb Company (BMY) reported $3,160,000 in lobbying expenditures for Q2 2026, addressing issues such as drug pricing, intellectual property reform, and the Inflation Reduction Act. The article also details recent congressional stock trading, insider transactions, hedge fund …

Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker

Bristol Myers Squibb plans to construct "the most powerful AI factory in life sciences" with Nvidia's assistance, marking its expanded collaboration to enhance AI capabilities for complex pharmaceutical problems. Meanwhile, Samsung Biologics is moving to acquire PolyPeptide Group for approximately $1.8 billion, a strategic …

Bristol Myers Squibb is deploying NVIDIA's most powerful AI computing system to speed drug discovery

Bristol Myers Squibb is expanding its computing infrastructure by deploying a second NVIDIA DGX SuperPOD built on DGX Vera Rubin NVL72 systems, which provides ten times greater performance per megawatt and will significantly accelerate drug discovery. This investment extends an existing three-year partnership with …

Bristol Myers Squibb Expands Partnership with Nvidia | PharmExec

Bristol Myers Squibb is significantly expanding its AI computing infrastructure through a partnership with Nvidia, aiming to create the most powerful AI factory in life sciences. This initiative will leverage Nvidia DGX SuperPOD systems to accelerate research across multiple therapeutic areas, with AI agents …

MYE stock holds recent gains as Myers Industries emphasizes margins and cash flow

Myers Industries (MYE) stock shows resilience as the company prioritizes margin expansion and strong cash flow, even with modest revenue declines. Recent financial reports highlight improved profitability, disciplined capital allocation, and a stronger balance sheet. This strategic focus aims to support MYE stock's valuation …

Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory

Bristol Myers Squibb (BMS) is significantly expanding its collaboration with Nvidia by deploying DGX SuperPOD with Vera Rubin NVL72 systems, creating what it claims is the most powerful AI computing infrastructure in life sciences. This aims to accelerate drug discovery and development across various …

Bristol Myers boosts AI capacity with expanded use of Nvidia systems

Bristol Myers Squibb (BMY) has expanded its artificial intelligence capabilities by implementing Nvidia's (NVDA) DGX SuperPOD with DGX Vera Rubin NVL72 systems. This move is expected to enhance the drugmaker's operations, leveraging Nvidia's supercomputing infrastructure.

Bristol Myers Squibb Deploys NVIDIA Vera Rubin AI Factory To Accelerate Drug Discovery

Bristol Myers Squibb is expanding its use of artificial intelligence for drug discovery by deploying a second NVIDIA DGX SuperPOD, an "AI factory" built on NVIDIA DGX Vera Rubin NVL72 systems. This initiative aims to provide all scientists with access to a unified AI …

Bristol Partners With Nvidia on AI Factory for Drug Development

Bristol Myers Squibb Co. is expanding its partnership with Nvidia Corp. to enhance the computing power of its AI factory, aiming to accelerate the development of new medicines. This collaboration is part of a broader trend where the chipmaker partners with the pharma industry …

Nvidia partners with Bristol-Myers Squibb to build AI supercomputer for drug discovery

Bristol-Myers Squibb (BMS) has partnered with Nvidia to establish a dedicated AI supercomputer for drug discovery, leveraging Nvidia's DGX SuperPOD technology. This "AI Center of Excellence" has been operational since March 2024, focusing on oncology research and predicting patient outcomes in immuno-oncology, and has …

Bristol Myers buys Nvidia's latest AI computing system for drug research

Bristol Myers Squibb announced its acquisition of Nvidia's cutting-edge DGX SuperPOD computing system, based on its new Vera Rubin architecture, to enhance AI-driven drug discovery and development. The pharmaceutical company aims to accelerate the identification of drug targets and improve success rates in clinical …

Bristol Myers Squibb Building Life Science Industry’s Most Advanced AI Factory on NVIDIA Vera Rubin

Bristol Myers Squibb (BMS) is significantly expanding its AI capabilities by deploying a second NVIDIA DGX SuperPOD, specifically built on eight DGX Vera Rubin NVL72 systems, to create the life science industry's most advanced AI factory. This initiative aims to democratize AI access for …

Trading Systems Reacting to (MYE) Volatility

This article provides an in-depth analysis of Myers Industries Inc. (NYSE: MYE) volatility, highlighting positive near-term sentiment that could shift to neutrality mid-term and eventually a long-term positive bias. It details AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with …